Abstract
Statins constitute the first-line medication in the primary and secondary prevention of cardiovascular accidents in patients with hypercholesterolemia, reducing by 25-30% the risk of myocardial infarction, ischemic stroke and cardiovascular lethality. Clinical studies over the past 10-15 years have demonstrated the likelihood of developing de novo diabetes after statin use. From these considerations, a series of problems are addressed, such as: Is the diabetogenic effect specific to the class of statins?; Does it depend on the dose used?; What is the benefit/risk ratio?; Which patients are more prone to developing diabetes?; what are the mechanisms of diabetes development?; Are there needed or developed diabetes prevention strategies for statin treatment?; Is it necessary to change the tactics of using statins in the development of diabetes?
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
